DOI:
10.1055/s-00000125
Senologie - Zeitschrift für Mammadiagnostik und -therapie
LinksClose Window
References
Goldhirsch A, Gelber RD, Piccard-Gebhart MJ et al.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
Lancet 2013;
382: 1021-1028
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.